经济观察网据方盛制药（603998）8月11日公告，方盛制药控股子公司广东方盛融科药业有限公司自主 研发的中药1.1类创新药紫英颗粒，近日收到国家药监局核准签发的《药物临床试验批准通知书》。 紫英颗粒拟用于治疗盆腔炎性疾病后遗症-慢性盆腔痛(湿热瘀结证)，适应症包括下腹隐痛、腰骶胀痛、 带下量多色黄质稠、低热起伏、经期腹痛加重等。 截至目前，该产品尚未在国内外上市，累计研发投入约847.17万元。 ...

开普检测：上半年净利润增长3.73% 拟10派3元 8月11日，开普检测（003008）发布2025年半年度报告，公司上半年实现营业收入1.11亿元，同比增长 3.23%；实现归属于上市公司股东的净利润4078.98万元，同比增长3.73%。公司拟向全体股东每10股派 发现金红利3元（含税）。 资料显示，开普检测成立于2005年1月，主营业务是新型电力系统装备的检测服务、其他技术服务以及 检测设备销售等。 所属行业：社会服务–专业服务–检测服务 新天绿能：7月发电量同比增加9.32% 8月11日，春光科技（603657）发布公告称，公司全资子公司苏州尚腾科技制造有限公司拟通过竞拍方 式取得苏州市吴中区胥口镇的土地使用权，并计划投资不超过10亿元建设年产清洁电器制品800万台的 新建项目。 资料显示，春光科技成立于2000年7月，主营业务是清洁电器软管、配件及整机ODM/OEM产品的研 发、生产和销售。 所属行业：家用电器–家电零部件Ⅱ–家电零部件Ⅲ 方盛制药：控股子公司紫英颗粒药物临床试验获批准 8月11日，方盛制药（603998）发布公告称，控股子公司广东方盛融科药业有限公司研发的中药创新药 紫英颗粒收到国 ...

重要新闻提示 北京经济技术开发区发布《北京经济技术开发区关于推动具身智能机器人创新发展的若干措施》 财经新闻 1. "北京亦庄"公众号8月10日消息称，9日，在2025世界机器人大会"产业发展"主论坛上，北京经济技术 开发区发布具身智能社会实验计划，并配套发布《北京经济技术开发区关于推动具身智能机器人创新发 展的若干措施》，全方位支持企业发展，精准赋能具身智能机器人产业发展。 2. 据新华社报道，网络平台数据显示，截至8月10日16时32分，2025年暑期档（6月—8月）电影总票房 （含预售）突破85亿元。 3. Wind数据显示，本周，A股市场将有34只股票面临解禁，合计解禁数量为30.57亿股；按最新收盘价 计算，合计解禁市值为2325.10亿元，周环比增加149.66%。从解禁股情况来看，海光信息将解禁市值超 1900亿元，智微智能将解禁市值超90亿元，智微智能、满坤科技、巍华新材、海光信息流通盘均将增加 超100%。 据新华社报道，截至8月10日16时32分，2025年暑期档（6月—8月）电影总票房（含预售）突破85亿元 开普检测（003008）：公司拟以1.04亿股为基数，向全体股东每10股派发现金 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603998 证券简称：方盛制药 公告编号：2025-067 湖南方盛制药股份有限公司 关于控股子公司中药创新药研发项目获得药物临床试验批准通知书的公告 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2025年5月22日受理的紫英颗粒 临床试验申请符合药品注册的有关要求，在进一步完善临床试验方案的基础上，同意本品开展用于盆腔 炎性疾病后遗症-慢性盆腔痛的临床试验。 二、新药的相关情况 本品系多年治疗盆腔炎的临床经验方审订而成。用于盆腔炎性疾病后遗症-慢性盆腔痛（湿热瘀结 证），症见下腹隐痛、腰骶胀痛、带下量多，色黄质稠、低热起伏、经期腹痛加重、胸闷纳呆、口干、 大便溏或便秘、小便黄赤者。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 近日，湖南方盛制药股份有限公司（以下简称"公司"或"方盛制药"）控股子公司广东方盛融科药业有限 公司（以下简称"方盛融科"）中药创新药研发项目紫英颗粒收到国家药品监督管理局核准签发的《药物 临床试验批准通知书》。现将相关 ...

佳创视讯：实控人拟变更为毛广甫与李莉夫妇 8月11日复牌 佳创视讯晚间公告，8月7日，公司控股股东、实控人陈坤江与李莉、毛广甫签署《控制权变更框架 协议》。若此次控制权变更事项顺利推进并实施完成，公司控股股东、实控人将由陈坤江变更为毛广 甫与李莉夫妇。公司股票8月11日复牌。 中国核电：浙江金七门核电站1号机组浇筑核岛第一罐混凝土 2025.08. 10 8月10日晚间，沪深两市多家上市公司发布公告，以下是第一财经对一些重要公告的汇总，供投资者 参考。 【品大事】 中国核电晚间公告，公司控股投资的中核浙能能源有限公司浙江金七门核电站1号机组已于2025年8 月10日浇筑核岛第一罐混凝土（简称FCD）。浙江金七门核电站1号机组采用我国自主知识产权 的"华龙一号"核电技术，单台机组额定容量为121.5万千瓦，电站设计运行寿命为60年。该机组 FCD后，公司控股在建核电机组数量将达到13台，装机容量将达到1513.8万千瓦。 *ST赛隆：因公司控制权已变更 董事长及部分高管辞职 *ST赛隆晚间公告，因公司控制权已发生变更，公司近日收到董事长兼总裁蔡南桂，董事唐霖，董事 兼常务副总裁刘达文，董事兼副总裁李剑峰，董事、 ...

Group 1 - Liyang Chip's shareholders plan to reduce their holdings by a total of up to 3.94% of the company's shares [2] - New Tian Green Energy reported a 9.32% year-on-year increase in power generation for July, totaling 84.42 million megawatt-hours [3] - Springlight Technology plans to invest up to 1 billion yuan in a new project to produce 8 million clean electrical products annually [5] Group 2 - Industrial Fulian reported a net profit of 12.113 billion yuan for the first half of the year, a year-on-year increase of 38.61% [8] - Yanjing Beer achieved a net profit of 1.103 billion yuan in the first half of the year, up 45.45% year-on-year [11] - Changqing Co. reported a net profit of 42.278 million yuan for the first half of the year, a significant increase of 117.75% [9] Group 3 - Seiyun Circuit plans to invest 125 million yuan to acquire a 3.82% stake in Shenzhen New Sound Semiconductor [6] - Crystal New Materials reported a net profit of 37.6744 million yuan for the first half of the year, a decrease of 7.3% year-on-year [7] - Kaipu Testing reported a net profit of 40.7898 million yuan for the first half of the year, a year-on-year increase of 3.73% [10]

Corporate Changes - Jiachuan Vision's actual controller is set to change to Mao Guangfu and Li Li couple, with stock resuming trading on August 11 [3] - *ST Sailong announced that due to a change in control, the chairman and several executives have resigned [5] Nuclear Power Development - China Nuclear Power announced that the first concrete for the nuclear island of the Zhejiang Jin Qimen Nuclear Power Plant Unit 1 was poured on August 10, 2025, with a capacity of 1.215 million kilowatts [4] Renewable Energy Expansion - Yunnan Energy Investment reported that the first batch of wind turbines for the Yongning Wind Farm expansion project has been connected to the grid, increasing total installed capacity to 1.85435 million kilowatts [6] New Projects - Chunguang Technology plans to invest up to 1 billion yuan in a new project to produce 8 million clean electrical appliances annually [7] - Fangsheng Pharmaceutical's subsidiary received approval for clinical trials of a new drug, Ziying Granules, for treating pelvic inflammatory disease [8] Financial Performance - Changqing Co. reported a net profit of 42.28 million yuan for the first half of 2025, a year-on-year increase of 117.75% [10] - Yanjing Beer achieved a net profit of 1.103 billion yuan in the first half of 2025, up 45.45% year-on-year [12] - Industrial Fulian reported a net profit of approximately 12.113 billion yuan, a 38.61% increase year-on-year [13] - Kaipu Testing's net profit increased by 3.73% year-on-year, with a proposed cash dividend of 3 yuan per 10 shares [14] - Jinghua New Materials reported a net profit of 37.67 million yuan, a decrease of 7.3% year-on-year [15] - Baiwei Storage reported a net loss of 226 million yuan in the first half of 2025, compared to a profit of 283 million yuan in the same period last year [16] - Xintian Green Energy's power generation in July increased by 9.32% year-on-year [17] Shareholding Changes - Lu Wei Optoelectronics' actual controller and major shareholders committed not to reduce their holdings within six months [19] - Liyang Chip's shareholders plan to collectively reduce their holdings by up to 3.94% [20] - Longlide's shareholder plans to reduce holdings by up to 1.9% [21] - Yinbao Shanneng's shareholder plans to reduce holdings by up to 1.54% [22] - Heda Technology's shareholder plans to reduce holdings by up to 1.1% [23] - Huizhiwei's shareholder plans to reduce holdings by up to 1% [24] - Nanjing Julong's specific shareholder plans to reduce holdings by 0.87% [25] - Furan Energy's shareholder plans to reduce holdings by up to 0.37% [26] - Xingrui Technology's shareholders plan to reduce holdings by up to 497,000 shares [27] - Mengjie Co.'s general manager plans to reduce holdings by up to 80,110 shares [28] - Yuanda Holdings' vice chairman plans to reduce holdings by 80,000 shares [29] - Henghua Technology's director plans to reduce holdings by up to 92,800 shares [30] - Silicon Treasure Technology's executives plan to reduce holdings by up to 77,300 shares [31]

Company Highlights - Industrial Fulian reported a 39% year-on-year increase in net profit for the first half of the year, with revenue reaching 360.76 billion yuan, a 35.58% increase. The GB200 series products have achieved mass production, and server revenue grew over 50% in Q2 [2] - Fangsheng Pharmaceutical's subsidiary received approval for clinical trials of its innovative traditional Chinese medicine, Ziying Granules, aimed at treating chronic pelvic pain [2] - Jiachuan Vision announced a potential change in control to Mao Guangfu and Li Li, with stock resuming trading on August 11, 2025 [3] Investment & Agreements - Chunguang Technology plans to invest up to 1 billion yuan in a project to produce 8 million clean electrical appliances annually [4] - Shiyun Electric plans to invest 125 million yuan to acquire a 3.82% stake in Shenzhen Xinsong Semiconductor [4] Shareholding Changes & Buybacks - Liyang Chip shareholders plan to collectively reduce their holdings by up to 3.94% [6] - Baiwei Storage intends to repurchase shares worth between 20 million and 40 million yuan to reduce registered capital [6] Performance & Financials - Jinghua New Materials reported a 7.3% decline in net profit for the first half of the year, with revenue of 947 million yuan, a 10.53% increase [7] - Yanjing Beer achieved a 45.45% increase in net profit, reaching 1.103 billion yuan, with revenue of 8.558 billion yuan, a 6.37% increase [7] - Baiwei Storage reported a net loss of 226 million yuan for the first half of the year, despite a 13.7% increase in revenue to 3.912 billion yuan [9] Other Developments - China Nuclear Power announced the completion of the first concrete pour for the nuclear island of the Zhejiang Jin Qimen Nuclear Power Plant's Unit 1 [8] - *ST Sailong's chairman and several executives resigned following a change in company control [10]

Core Viewpoint - Fangsheng Pharmaceutical (603998) announced that its subsidiary, Guangdong Fangsheng Rongo Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of its innovative traditional Chinese medicine, Ziying Granules, which is based on years of clinical experience in treating pelvic inflammatory disease [1] Company Summary - Fangsheng Pharmaceutical's subsidiary has developed Ziying Granules, which is aimed at treating pelvic inflammatory disease [1] - The approval for clinical trials marks a significant milestone in the company's drug development efforts [1]

Core Viewpoint - Hunan Fangsheng Pharmaceutical Co., Ltd. announced that its subsidiary, GuangDong Fangsheng R&D Pharmaceutical Co., Ltd., received approval for clinical trials of its innovative traditional Chinese medicine, Ziying Granules, aimed at treating chronic pelvic pain due to pelvic inflammatory disease [2][3]. Drug Information - Drug Name: Ziying Granules - Dosage Form: Granule - Registration Category: Traditional Chinese Medicine Class 1.1 - Application Matter: Clinical Trials - Acceptance Number: CXZL2500030 - Approval Conclusion: The clinical trial application for Ziying Granules was accepted on May 22, 2025, and is approved to proceed with trials for chronic pelvic pain [2][3]. New Drug Details - Ziying Granules are based on clinical experience for treating pelvic inflammatory disease and are intended for chronic pelvic pain with symptoms including lower abdominal pain, lumbar discomfort, and abnormal discharge [3]. Market Situation for Similar Drugs - The market for traditional Chinese medicine in gynecological diseases has maintained sales around 5.7 billion yuan from 2020 to 2023, with a growth rate of 3.38% in the first three quarters of 2024. The market share for gynecological regulation drugs is 47.38%, with a year-on-year sales increase of 6.61% [3]. - The demand for drugs treating pelvic inflammatory disease is significant, with over 3.2 billion yuan in sales for traditional Chinese medicine gynecological drugs in urban pharmacies in the first three quarters of 2024, despite a 6.40% year-on-year decline [3]. Competitor Products - Current treatments for chronic pelvic pain include various products such as Fuke Qianjin Tablets/Capsules, Guizhi Fuling Capsules/Pills/Tabs, and others, with sales data indicating significant market presence [4][5].